These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 15575955

  • 1. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M.
    BMC Pharmacol; 2004 Dec 02; 4():31. PubMed ID: 15575955
    [Abstract] [Full Text] [Related]

  • 2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 4. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T.
    Cancer Res; 1995 Jun 01; 55(11):2299-303. PubMed ID: 7757979
    [Abstract] [Full Text] [Related]

  • 5. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb 01; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 6. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M, Sehested M, Jensen PB.
    Mol Pharmacol; 1999 Mar 01; 55(3):424-31. PubMed ID: 10051525
    [Abstract] [Full Text] [Related]

  • 7. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH.
    Anticancer Drug Des; 2001 Dec 01; 16(6):305-15. PubMed ID: 12375883
    [Abstract] [Full Text] [Related]

  • 8. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B, Jensen PB, Sehested M.
    Cancer Chemother Pharmacol; 1996 Dec 01; 38(3):203-9. PubMed ID: 8646793
    [Abstract] [Full Text] [Related]

  • 9. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB, Abram ME, Chee GL, Huebner E, Byard EH, Barnabé N, Ferrans VJ, Yu ZX, Yalowich JC.
    J Pharmacol Exp Ther; 2000 Nov 01; 295(2):474-83. PubMed ID: 11046078
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures.
    Robbie MA, Baguley BC, Denny WA, Gavin JB, Wilson WR.
    Cancer Res; 1988 Jan 15; 48(2):310-9. PubMed ID: 2825971
    [Abstract] [Full Text] [Related]

  • 11. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ, Smith PJ.
    Cancer Res; 1988 Jan 15; 48(2):297-303. PubMed ID: 2825970
    [Abstract] [Full Text] [Related]

  • 12. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
    Frankenberg-Schwager M, Becker M, Garg I, Pralle E, Wolf H, Frankenberg D.
    Radiat Res; 2008 Dec 15; 170(6):784-93. PubMed ID: 19138034
    [Abstract] [Full Text] [Related]

  • 13. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
    Hirota H, Gosky D, Berger NA, Chatterjee S.
    Int J Oncol; 2002 Feb 15; 20(2):311-8. PubMed ID: 11788894
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH.
    Toxicology; 2009 Jan 08; 255(1-2):72-9. PubMed ID: 19010377
    [Abstract] [Full Text] [Related]

  • 15. Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds.
    van Hille B, Clerc X, Creighton AM, Hill BT.
    Br J Cancer; 1999 Nov 08; 81(5):800-7. PubMed ID: 10555749
    [Abstract] [Full Text] [Related]

  • 16. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 17. Production of protein-associated DNA breaks by 10-[diethylaminopropylamino]-6-methyl-5H-pyrido[3',4':4,5]pyrrolo [2,3-g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors.
    Pierson V, Pierre A, Pommier Y, Gros P.
    Cancer Res; 1988 Mar 15; 48(6):1404-9. PubMed ID: 2830964
    [Abstract] [Full Text] [Related]

  • 18. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC, Ashorn CL, Chan D, Zwelling LA.
    Cancer Res; 1989 Apr 15; 49(8):2052-8. PubMed ID: 2539251
    [Abstract] [Full Text] [Related]

  • 19. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M, Chan D, Freireich EJ, Marton LJ, Zwelling LA.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [Abstract] [Full Text] [Related]

  • 20. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
    Rowe TC, Chen GL, Hsiang YH, Liu LF.
    Cancer Res; 1986 Apr 15; 46(4 Pt 2):2021-6. PubMed ID: 3004716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.